Alliance Wealth Advisors LLC UT Cuts Position in Ryan Specialty Holdings, Inc. (NYSE:RYAN)

Alliance Wealth Advisors LLC UT reduced its holdings in Ryan Specialty Holdings, Inc. (NYSE:RYAN - Free Report) by 44.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,267 shares of the company's stock after selling 6,526 shares during the quarter. Alliance Wealth Advisors LLC UT's holdings in Ryan Specialty were worth $530,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in RYAN. Jennison Associates LLC boosted its holdings in Ryan Specialty by 60.2% in the third quarter. Jennison Associates LLC now owns 1,025,063 shares of the company's stock worth $68,054,000 after acquiring an additional 385,366 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Ryan Specialty by 107.5% in the third quarter. JPMorgan Chase & Co. now owns 459,464 shares of the company's stock worth $30,504,000 after purchasing an additional 238,064 shares during the last quarter. Geneva Partners LLC purchased a new position in shares of Ryan Specialty in the third quarter worth $2,537,000. Bar Harbor Wealth Management raised its stake in shares of Ryan Specialty by 5.9% in the fourth quarter. Bar Harbor Wealth Management now owns 168,871 shares of the company's stock worth $10,835,000 after purchasing an additional 9,482 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Ryan Specialty by 1.1% in the third quarter. Barclays PLC now owns 1,641,743 shares of the company's stock worth $108,994,000 after purchasing an additional 17,267 shares during the last quarter. 84.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Ryan Specialty

In other news, Director Nicholas Dominic Cortezi sold 31,409 shares of Ryan Specialty stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $65.64, for a total value of $2,061,686.76. Following the completion of the transaction, the director now owns 2,697 shares in the company, valued at approximately $177,031.08. The trade was a 92.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David P. Bolger sold 7,055 shares of the firm's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $70.88, for a total value of $500,058.40. Following the sale, the director now directly owns 78,149 shares of the company's stock, valued at $5,539,201.12. This represents a 8.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 323,506 shares of company stock worth $21,407,851 in the last quarter. 11.10% of the stock is owned by corporate insiders.

Ryan Specialty Price Performance

NYSE RYAN traded down $0.27 during trading on Friday, hitting $68.24. 637,807 shares of the stock traded hands, compared to its average volume of 955,283. The company has a market capitalization of $17.87 billion, a P/E ratio of 88.63, a price-to-earnings-growth ratio of 1.19 and a beta of 0.72. The firm has a 50-day simple moving average of $66.12 and a 200-day simple moving average of $66.87. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 2.40. Ryan Specialty Holdings, Inc. has a 12-month low of $42.68 and a 12-month high of $75.97.

Analyst Upgrades and Downgrades

RYAN has been the subject of a number of research reports. Wells Fargo & Company reduced their price objective on Ryan Specialty from $68.00 to $64.00 and set an "equal weight" rating for the company in a research report on Tuesday, January 14th. Barclays upped their price objective on Ryan Specialty from $76.00 to $88.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. Keefe, Bruyette & Woods reduced their price target on Ryan Specialty from $79.00 to $77.00 and set an "outperform" rating for the company in a research report on Friday, January 10th. Finally, Morgan Stanley assumed coverage on Ryan Specialty in a research report on Thursday, December 5th. They issued an "overweight" rating and a $90.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $74.40.

Ryan Specialty Company Profile

Ryan Specialty Holdings, Inc operates as a service provider of specialty products and solutions for insurance brokers, agents, and carriers in the United States, Canada, the United Kingdom, Europe, and Singapore. It offers distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.